Anavex Life Sciences Corp (AVXL)

[rocalinda]

Dude,

At least do some DD before posting stuff.

The biotech's big sell revolves around azeliragon, which Pfizer dumped after a trial using a 20-mg dose was stopped after signs of cognitive worsening developed in patients. But the company, run by Stephen Holcombe with former Pfizer CEO Jeff Kindler acting as executive chairman--says the 5-mg dose demonstrated an improvement for a key ADAS-Cog score on cognition, and that's the window it's shooting for among patients with a mild form of the disease.

"This is a very, very tight window between what could be a good effect and what is certainly a very bad one," noted biotech blogger Derek Lowe, "which is surely why Pfizer dropped the compound like it was giving off gamma rays and has not returned to it."